NCT06644625 CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
| NCT ID | NCT06644625 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,665 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2035-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,665 participants in total. It began in 2025-03-01 with a primary completion date of 2035-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
Eligibility Criteria
SCREENING Inclusion Criteria: * Age 30 years or older at the time of consent * Either: 1. Self-identify as Black and/or African American OR 2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia * Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately * Reside in Charlotte, NC, or the surrounding area, based on self-report SCREENING Exclusion Criteria: * Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS. LONGITUDINAL Inclusion Criteria: * Test positive for monoclonal gammopathy during screening portion of the study * Consent to the longitudinal portion of the study LONGITUDINAL Exclusion Criteria: * The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.
Contact & Investigator
Manisha Bhutani, MD
PRINCIPAL INVESTIGATOR
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06644625 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06644625 currently recruiting?
Yes, NCT06644625 is actively recruiting participants. Contact the research team at margarita.dzhanumova@atriumhealth.org for enrollment information.
Where is the NCT06644625 trial being conducted?
This trial is being conducted at Charlotte, United States.
Who is sponsoring the NCT06644625 clinical trial?
NCT06644625 is sponsored by Wake Forest University Health Sciences. The principal investigator is Manisha Bhutani, MD at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. The trial plans to enroll 1,665 participants.